IN2012DN03093A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03093A
IN2012DN03093A IN3093DEN2012A IN2012DN03093A IN 2012DN03093 A IN2012DN03093 A IN 2012DN03093A IN 3093DEN2012 A IN3093DEN2012 A IN 3093DEN2012A IN 2012DN03093 A IN2012DN03093 A IN 2012DN03093A
Authority
IN
India
Prior art keywords
construct
host cell
protease
precursor protein
capsid precursor
Prior art date
Application number
Other languages
English (en)
Inventor
Charleston Bryan
Jones Ian
Original Assignee
Pirbright Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pirbright Inst filed Critical Pirbright Inst
Publication of IN2012DN03093A publication Critical patent/IN2012DN03093A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747Apoptosis related proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32111Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32111Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32123Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4703Regulators; Modulating activity
    • G01N2333/4704Inhibitors; Supressors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN3093DEN2012 2009-10-20 2010-09-24 IN2012DN03093A (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0918375.7A GB0918375D0 (en) 2009-10-20 2009-10-20 Construct
PCT/GB2010/001807 WO2011048353A2 (en) 2009-10-20 2010-09-24 Construct

Publications (1)

Publication Number Publication Date
IN2012DN03093A true IN2012DN03093A (sr) 2015-09-18

Family

ID=41462637

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3093DEN2012 IN2012DN03093A (sr) 2009-10-20 2010-09-24

Country Status (15)

Country Link
US (1) US9243230B2 (sr)
EP (1) EP2491118B1 (sr)
JP (1) JP2013507948A (sr)
KR (1) KR101818934B1 (sr)
CN (1) CN102834507B (sr)
AU (1) AU2010309648A1 (sr)
BR (1) BR112012009475B1 (sr)
CO (1) CO6551678A2 (sr)
ES (1) ES2652443T3 (sr)
GB (1) GB0918375D0 (sr)
HU (1) HUE035889T2 (sr)
IN (1) IN2012DN03093A (sr)
RU (1) RU2565537C2 (sr)
WO (1) WO2011048353A2 (sr)
ZA (1) ZA201202882B (sr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201111183D0 (en) 2011-06-30 2011-08-17 Animal Health Inst Peptide
MX363409B (es) 2011-11-03 2019-03-20 Sentinext Therapeutics Sdn Bhd Antigenos y vacunas dirigidos contra enterovirus hunanos.
SG10201810400TA (en) * 2012-09-05 2018-12-28 Medicago Inc Picornavirus-like particle production in plants
US10294277B2 (en) 2013-03-26 2019-05-21 The Pirbright Institute Stabilised FMDV capsids
SG11201609062PA (en) * 2014-04-29 2016-11-29 Nat Health Research Institutes Adenoviral vector-based vaccine against enterovirus infection
WO2016202828A1 (en) * 2015-06-15 2016-12-22 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine
US9975926B2 (en) 2015-12-08 2018-05-22 The United States of America, as Represented by the Secretary of Homeland Security Methods of making and using vaccines utilizing minicircle DNA expression vectors for production of foot-and-mouth-disease virus proteins and virus-like particles
US10385319B2 (en) * 2016-09-08 2019-08-20 The Governement of the United States of America, as represented by the Secretary of Homeland Security Modified foot-and-mouth disease virus 3C proteases, compositions and methods thereof
US10435695B2 (en) 2016-09-08 2019-10-08 The Government of the United States of America, as represented by the Secretary of Homeland Security Fusion protein comprising Gaussia luciferase, translation interrupter sequence, and interferon amino acid sequences
US10308927B2 (en) * 2017-01-17 2019-06-04 The United States of America, as Represented by the Secretary of Homeland Security Processing of a modified foot-and-mouth disease virus P1 polypeptide by an alternative protease
WO2019092027A1 (en) * 2017-11-09 2019-05-16 Boehringer Ingelheim Vetmedica Gmbh Sapelovirus immunogenic compositions and uses thereof
GB201812474D0 (en) 2018-07-31 2018-09-12 Autolus Ltd Nucleic acid construct
JPWO2020067027A1 (ja) * 2018-09-28 2021-08-30 一般財団法人阪大微生物病研究会 Vlp発現cho細胞株の構築
CN116685687A (zh) 2020-10-22 2023-09-01 英特维特国际股份有限公司 杆状病毒表达载体
JP2023549461A (ja) 2020-10-22 2023-11-27 インターベット インターナショナル ベー. フェー. バキュロウイルス発現ベクター
CN117881423A (zh) 2021-08-20 2024-04-12 英特维特国际股份有限公司 产生口蹄疫病毒病毒样颗粒的方法
CN117897170A (zh) 2021-08-20 2024-04-16 英特维特国际股份有限公司 具有稳定化突变的fmdv病毒样颗粒
EP4387661A1 (en) 2021-08-20 2024-06-26 Intervet International B.V. Method of producing a foot and mouth disease virus virus-like particle
WO2023020738A1 (en) 2021-08-20 2023-02-23 The Pirbright Institute Fmdv virus-like particle with double stabilizing mutation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19712899C1 (de) 1997-03-27 1998-12-10 Christian Dr Probst Verfahren zur Herstellung nichtinfektiöser rekombinanter Picornavirus-Partikel
RU2143921C1 (ru) * 1999-04-21 2000-01-10 Всероссийский научно-исследовательский институт защиты животных Вакцина против ящура типа а и способ ее изготовления
FR2810888B1 (fr) 2000-06-29 2004-07-30 Merial Sas Vaccin contre la fievre aphteuse
ES2307345B1 (es) * 2004-01-21 2009-11-13 Consejo Sup. Investig. Cientificas Capsidas vacias quimericas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
EP1632247A1 (en) 2004-09-03 2006-03-08 Consejo Superior De Investigaciones Cientificas Nucleic acid sequences encoding FMDV proteins capable of associating into a virus-like particle
NZ542111A (en) 2005-08-30 2008-04-30 Otago Innovation Ltd Novel assay

Also Published As

Publication number Publication date
KR20120069756A (ko) 2012-06-28
CN102834507B (zh) 2016-09-07
ES2652443T3 (es) 2018-02-02
HUE035889T2 (en) 2018-05-28
CN102834507A (zh) 2012-12-19
CO6551678A2 (es) 2012-10-31
EP2491118B1 (en) 2017-11-08
ZA201202882B (en) 2013-06-26
BR112012009475A2 (pt) 2015-09-15
RU2012120700A (ru) 2013-12-10
WO2011048353A2 (en) 2011-04-28
RU2565537C2 (ru) 2015-10-20
BR112012009475B1 (pt) 2020-06-09
US9243230B2 (en) 2016-01-26
GB0918375D0 (en) 2009-12-02
JP2013507948A (ja) 2013-03-07
US20120258133A1 (en) 2012-10-11
AU2010309648A1 (en) 2012-05-03
WO2011048353A3 (en) 2011-09-29
EP2491118A2 (en) 2012-08-29
KR101818934B1 (ko) 2018-01-17

Similar Documents

Publication Publication Date Title
IN2012DN03093A (sr)
MX339581B (es) Variantes de subtilasa.
MX352023B (es) Variantes de alfa-amilasa con estabilidad mejorada.
MX2013003681A (es) Ácidos nucleicos manipulados y métodos de uso de los mismos.
IN2014CN00688A (sr)
NZ597401A (en) Chimeric influenza virus-like particles comprising hemagglutinin
MX2012006096A (es) Polipeptidos que tienen actividad glucoamilasa y polinucleotidos que codifican para los mismos.
MX2014004598A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MX351175B (es) Detergente líquido para lavar vajillas estable al almacenamiento que contiene proteasa y amilasa.
EA201100225A1 (ru) Новые регуляторные элементы
MX354516B (es) Vectores que codifican el factor de viabilidad de conos derivado de bastones.
EP3805348A3 (en) Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
MX2012003473A (es) Polipeptidos que tienen actividad celulitica mejorada y polinucleotidos que codifican para los mismos.
MX354704B (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MX369726B (es) Polipéptidos con actividad proteasa.
MX2009010492A (es) Elementos de vector de expresion recombinante (reves) para mejorar la expresion de proteinas recombinantes en celulas huesped.
CO6430475A2 (es) Polipéptidos que tienen actividad de celulasa
MX2012006095A (es) Polipeptidos que tienen actividad glucoamilasa y polinucleotidos que codifican para los mismos.
MX349517B (es) Polipeptidos que tienen actividad de proteasa y polinucleotidos que codifican los mismos.
MX2016008258A (es) Celulas eucariotas novedosas y metodos para la expresion recombinante de un producto de interes.
MX350391B (es) Polipeptidos que poseen actividad proteasa y polinucleotidos que los codifican.
EA201200186A1 (ru) Вектор, содержащий промотор маннозы, и промотор маннозы
WO2010028093A3 (en) Use of a truncated elf-5a1 polynucleotide to induce apoptosis in cancer cells
WO2010133668A3 (en) Eukaryotic host cell comprising an expression enhancer
NZ702345A (en) Lentiviral vectors containing an mhc class i promoter